Results 71 to 80 of about 28,270 (206)

Effectiveness and Safety of Ticagrelor Implementation in Patients with Acute Coronary Syndrome undergoing Percutaneous Coronary Intervention: A Cohort Study in Western Denmark

The Lancet Regional Health. Europe, 2022
Summary: Background: Ticagrelor was introduced in Denmark in 2011 after randomised data showed its superiority over clopidogrel for patients with acute coronary syndrome (ACS). We assessed the effectiveness and safety of ticagrelor implementation in ACS
Pernille Gro Thrane, Kevin Kris Warnakula Olesen, Morten Würtz, Christine Gyldenkerne, Morten Madsen, Lisette Okkels Jensen, Bent Raungaard, Henrik Toft Sørensen, Troels Thim, Steen Dalby Kristensen, Michael Maeng   +10 more
doaj   +1 more source

Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease [PDF]

, 2017
International ...
Baumgartner, Iris,, Berger, Jeffrey S,, Blomster, Juuso, EUCLID Trial Steering Committee and Investigators, Fowkes, F Gerry R,, Gottsäter, Anders,, Heizer, Gretchen,, Held, Peter,, Hiatt, William R,, Jones, W Schuyler,, Katona, Brian G,, Lund University., Lund University., Mahaffey, Kenneth W,, Millegård, Marcus, Norgren, Lars,, Patel, Manesh R, Reist, Craig   +17 more
core   +3 more sources

P‐CAB vs. PPI for Upper Gastrointestinal Bleeding Prevention in Patients With Atherothrombotic Disease on Antithrombotic Therapy: A CDM Cohort Study

Alimentary Pharmacology &Therapeutics, EarlyView.
In patients with atherothrombotic disease on antithrombotic therapy, P‐CABs demonstrated a significantly superior protective effect against clinically significant upper GI haemorrhage compared to PPIs (aHR 0.22; p = 0.016). This real‐world study highlights P‐CABs as a more potent gastroprotective strategy for high‐risk populations requiring intensive ...
Min Joo Yoon, Soyoung Lee, Hye‐Kyung Jung, Min‐ho Kim, Suna Yu, Eui Sun Jeong, Chung Hyun Tae   +6 more
wiley   +1 more source

Compared efficacy of clopidogrel and ticagrelor in treating acute coronary syndrome: a meta-analysis

BMC Cardiovascular Disorders, 2018
Background & Aims Ticagrelor has been acknowledged as a new oral antagonist of P2Y12-adenosine diphosphate receptor, as a strategy with more rapid onset as well as more significant platelet inhibition function in acute coronary syndrome (ACS) patients ...
Dong Wang, Xiao-Hong Yang, Ji-Dong Zhang, Rui-Bin Li, Min Jia, Xiao-Ran Cui   +5 more
doaj   +1 more source

Comparison of Ticagrelor and Clopidogrel in Elective Coronary Stenting: A Double Blind Randomized Clinical Trial

Journal of Interventional Cardiology, 2023
Background. Dual antiplatelet therapy with a P2Y12 inhibitor (e.g., clopidogrel and ticagrelor) and aspirin is recommended for at least one year after percutaneous coronary intervention (PCI) to prevent further myocardial infarction and stent thrombosis ...
Mohammadjavad Mehdizadeh Parizi, Reza Golchin Vafa, Amin Ahmadi, Reza Heydarzade, Mehrdad Sadeghi, Amin Khademolhossseini, Farhang Amiri, Soroush Khoshnood Mansorkhani, Ali Tavan, Nazanin Hosseini, Mohammad Montaseri, Seyed Ali Hosseini, Javad Kojuri   +12 more
doaj   +1 more source

The potential for biased signalling in the P2Y receptor family of GPCRs

British Journal of Pharmacology, EarlyView.
The purinergic receptor family is primarily activated by nucleotides, and contains members of both the G protein coupled‐receptor (GPCR) superfamily (P1 and P2Y) and ligand‐gated ion channels (P2X). The P2Y receptors are widely expressed in the human body, and given the ubiquitous nature of nucleotides, purinergic signalling is involved with a plethora
Claudia M. Sisk, Simon Pitchford, Graham Ladds   +2 more
wiley   +1 more source

Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers. [PDF]

, 2019
BACKGROUND: Ticagrelor is an oral P2Y12 inhibitor that is used with aspirin to reduce the risk of ischemic events among patients with acute coronary syndromes or previous myocardial infarction.
Arnold, Susan E., Bhatt, Deepak L., Jennings, Lisa K., Lee, John S., Mays, Michael C., Pollack, Charles V., Umstead, Bret R., Weitz, Jeffrey I., Xu, Sherry   +8 more
core   +1 more source

Obesity in Classic Congenital Adrenal Hyperplasia: Mechanisms, Complications and Management

Clinical Endocrinology, EarlyView.
ABSTRACT Classic congenital adrenal hyperplasia (CCAH) is an autosomal recessive genetic disorder primarily caused by 21‐hydroxylase deficiency. Although the survival rate of patients has significantly improved with glucocorticoid replacement therapy, long‐term use of supraphysiological doses and multiple factors inherent to the disease itself have led
Jialin Mu, Yue Li, Meng Sun, Yulin Li, Panpan Li, Hui Zou   +5 more
wiley   +1 more source

P2Y12 receptor modulation of ADP‐evoked intracellular Ca2+ signalling in THP‐1 human monocytic cells [PDF]

, 2018
Background and purpose: The Gi‐coupled, ADP‐activated P2Y12 receptor is well characterised as playing a key role in platelet activation via crosstalk with P2Y1 in ADP‐evoked intracellular Ca2+ response.
Alexander, Alexander, Aungraheeta, Baqi, Ben Addi, Brinson, Campwala, Cattaneo, Communi, Communi, Curtis, Czerniecki, Dorsam, Erb, Giezen, Harding, Hardy, Husted, Jin, Kronlage, Mahaut-Smith, Mamedova, Mattana, Myers, Nylander, Sivaramakrishnan, Suplat, West, Zhang, Ziegler-Heitbrock   +29 more
core   +1 more source

Association of SGLT2 Inhibitor With Stroke in Type 2 Diabetes With Diabetic Retinopathy: A Multicenter Electronic Health Record Data Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Diabetic retinopathy (DR) is linked to elevated risks of cerebrovascular diseases. Whether sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) reduce stroke risk in patients with type 2 diabetes (T2D) and DR remains uncertain. Materials and Methods We conducted a retrospective cohort study using the TriNetX Research Network.
Kuo‐En Chen, Po‐Chun Wang, Hui‐An Lin, Sheng‐Feng Lin   +3 more
wiley   +1 more source